Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Catheter Precision Inc. (VTAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VTAK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.18% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.91M USD | Price to earnings Ratio 0.08 | 1Y Target Price 2 |
Price to earnings Ratio 0.08 | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta -0.21 | 52 Weeks Range 2.20 - 20.14 | Updated Date 10/17/2025 |
52 Weeks Range 2.20 - 20.14 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 33.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1338.68% |
Management Effectiveness
Return on Assets (TTM) -29.44% | Return on Equity (TTM) -184.52% |
Valuation
Trailing PE 0.08 | Forward PE - | Enterprise Value 5818891 | Price to Sales(TTM) 6.52 |
Enterprise Value 5818891 | Price to Sales(TTM) 6.52 | ||
Enterprise Value to Revenue 9.7 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 1487266 | Shares Floating 1209287 |
Shares Outstanding 1487266 | Shares Floating 1209287 | ||
Percent Insiders 3.56 | Percent Institutions 5.72 |
Upturn AI SWOT
Catheter Precision Inc.
Company Overview
History and Background
Catheter Precision, Inc. (VTAK) was founded in 2011. The company focuses on developing and commercializing innovative technologies for electrophysiology procedures, primarily for cardiac arrhythmias.
Core Business Areas
- PinPoint System: The PinPoint system, which is no longer a core product, aimed to provide a non-fluoroscopic, three-dimensional mapping system for cardiac catheter ablation procedures.
- VIVO System: The VIVO 3D imaging system, uses simple inputs to allow surgeons to gain insights before beginning a procedure.
- Lockbox Placements: Safe, accurate, reliable central venous catheter (CVC) placement.
Leadership and Structure
David Jenkins serves as the Chief Executive Officer. The company has a board of directors that oversees its strategic direction. Organizational structure consists of departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- VIVO System: The VIVO system provides non-invasive 3D imaging system used in pre-operative visualization for cardiac procedures. This market is competitive with companies like Abbott and Medtronic who offer similar imaging solutions, though VTAK focuses on niche areas. Market share data specifically for this product is difficult to determine precisely.
- Lockbox Placements: Safe, accurate, reliable central venous catheter (CVC) placement
Market Dynamics
Industry Overview
The electrophysiology market is growing, driven by increasing prevalence of cardiac arrhythmias like atrial fibrillation, and innovations in catheter ablation technologies.
Positioning
Catheter Precision occupies a smaller, niche position within the electrophysiology market, focusing on improving the accuracy and efficiency of catheter ablation procedures and pre-operative surgical planning.
Total Addressable Market (TAM)
The global electrophysiology market is estimated to be worth tens of billions of dollars, with projections for continued growth. Catheter Precision is positioned to capture a small segment of this market with its focused product offerings.
Upturn SWOT Analysis
Strengths
- Innovative Product Pipeline
- Potential for Improved Procedure Outcomes
- Strong Intellectual Property Portfolio
Weaknesses
- Limited Market Share
- Dependence on Regulatory Approvals
- High Cash Burn Rate
Opportunities
- Expansion into New Markets
- Strategic Partnerships
- Increased Adoption of Advanced Mapping Technologies
Threats
- Competition from Established Players
- Pricing Pressures
- Changes in Healthcare Regulations
Competitors and Market Share
Key Competitors
- ABT
- MDT
Competitive Landscape
Catheter Precision faces intense competition from larger, more established medical device companies. The company's competitive advantage lies in its focus on niche applications and novel technologies.
Growth Trajectory and Initiatives
Historical Growth: Insufficient data available.
Future Projections: Future growth will depend on factors like regulatory approvals, product adoption, and market conditions.
Recent Initiatives: Insufficient data available. Strategic initiatives would include partnerships, new product launches, and market expansion efforts.
Summary
Catheter Precision is a small medical device company that needs regulatory approvals to market its products. It operates in a competitive market dominated by established players. Success hinges on successful product launches, market adoption, and effective cost management. The company's innovative technologies provide a potential advantage. However, it remains a high-risk, high-reward investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Financial News Sources
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Catheter Precision Inc.
Exchange NYSE MKT | Headquaters Fort Mill, SC, United States | ||
IPO Launch date 2018-09-27 | CEO, Chief Commercial Officer & Executive Chairman Mr. David A. Jenkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 22 | |
Full time employees 22 | |||
Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also offers LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures. The company is based in Fort Mill, South Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.